PMID- 31977357
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1538-943X (Electronic)
IS  - 1058-2916 (Linking)
VI  - 66
IP  - 9
DP  - 2020 Sep/Oct
TI  - Comparison of Antithrombin III Products in Pediatric Patients Receiving 
      Extracorporeal Membrane Oxygenation.
PG  - 1042-1047
LID - 10.1097/MAT.0000000000001124 [doi]
AB  - The study investigated the safety and efficacy of two antithrombin III (ATIII) 
      products in pediatric patients receiving extracorporeal membrane oxygenation 
      (ECMO) by performing a retrospective analysis of patients who received either 
      recombinant ATIII (rATIII) or human-derived ATIII (hATIII). Twenty-two patients 
      were included in the study from January 2014 to September 2015 and all received 
      unfractionated heparin (UFH) as anticoagulation during ECMO. In total, 86 doses 
      of ATIII were included in the analysis in which 37 doses (43%) were rATIII and 49 
      doses (57%) were hATIII. Unfractionated heparin rates were also evaluated for all 
      cases (n = 86) at 24 hours post-ATIII supplementation. The UFH rate decreased 
      after the administration of both types of ATIII. However, neither the reduction 
      in UFH rate between the two ATIII products (p = 0.52) nor the UFH rates pre- and 
      post-ATIII supplementation at 24 hours (p = 0.08) reached statistical 
      significance. There was a significant difference in cost favoring the rATIII 
      product (p < 0.0001). An ad-hoc estimation of waste associated with ATIII 
      supplementation showed >$100,000 in financial loss of unused drug. Future studies 
      are warranted to evaluate the efficacy of ATIII supplementation in pediatric 
      ECMO.
FAU - Omecene, Nicole E
AU  - Omecene NE
AD  - From the School of Pharmacy, Department of Pharmacotherapy and Outcomes Science, 
      Virginia Commonwealth University, Richmond, Virginia.
FAU - Kishk, Omayma A
AU  - Kishk OA
AD  - Department of Pharmacy, University of Maryland Medical Center, Baltimore, 
      Maryland.
FAU - Lardieri, Allison B
AU  - Lardieri AB
AD  - School of Pharmacy, Department of Pharmacy Practice and Science, University of 
      Maryland, Baltimore, Maryland.
FAU - Walker, L Kyle
AU  - Walker LK
AD  - Division of Pediatric Critical Care Medicine, School of Medicine, University of 
      Maryland, Baltimore, Maryland.
FAU - Bhutta, Adnan T
AU  - Bhutta AT
AUID- ORCID: 0000-0003-3362-5835
AD  - Division of Pediatric Critical Care Medicine, School of Medicine, University of 
      Maryland, Baltimore, Maryland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
RN  - 0 (Anticoagulants)
RN  - 0 (Recombinant Proteins)
RN  - 0 (SERPINC1 protein, human)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antithrombin III/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Child
MH  - Extracorporeal Membrane Oxygenation/*adverse effects
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Male
MH  - Recombinant Proteins/*therapeutic use
MH  - Retrospective Studies
MH  - Thrombosis/etiology/*prevention & control
EDAT- 2020/01/25 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/01/25 06:00
PHST- 2020/01/25 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/01/25 06:00 [entrez]
AID - 00002480-202009000-00013 [pii]
AID - 10.1097/MAT.0000000000001124 [doi]
PST - ppublish
SO  - ASAIO J. 2020 Sep/Oct;66(9):1042-1047. doi: 10.1097/MAT.0000000000001124.